Most T-cell engagers in clinical development are derived from a small number of CD3-binding antibodies, such as SP34–2, limiting the potential to generate optimal immune synapses. To address this challenge, we developed a T-cell engager platform that includes hundreds of fully human CD3-binding antibodies with diverse binding properties.

In this case study, we present data on our largest panel of bispecific T-cell engagers to date, providing novel insights into how CD3-binding properties impact function. We leveraged these learnings to identify promising T-cell engagers for multiple tumor targets, two of which are shown here.